KCNA1

Potassium voltage-gated channel subfamily A member 1 · Q09470 · KCNA1 on Sugi Atlas →

6,331 patent compounds predicted against KCNA1, 4,950 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1945000 SCHEMBL1945000 1.00 10/20
SCHEMBL1945019 SCHEMBL1945019 1.00 10/20
SCHEMBL1945507 SCHEMBL1945507 1.00 10/20
SCHEMBL1945846 SCHEMBL1945846 1.00 10/20
SCHEMBL1946003 SCHEMBL1946003 1.00 10/20
SCHEMBL1946008 SCHEMBL1946008 1.00 10/20
SCHEMBL1947206 SCHEMBL1947206 1.00 10/20
SCHEMBL1947591 SCHEMBL1947591 1.00 10/20
SCHEMBL1948073 SCHEMBL1948073 1.00 10/20
SCHEMBL1945005 SCHEMBL1945005 0.92 10/20
SCHEMBL1945192 SCHEMBL1945192 0.92 10/20
SCHEMBL1944493 SCHEMBL1944493 0.92 10/20
SCHEMBL1949184 SCHEMBL1949184 0.88 10/20
SCHEMBL1945844 SCHEMBL1945844 0.86 10/20
SCHEMBL1946654 SCHEMBL1946654 0.84 10/20
SCHEMBL1946194 SCHEMBL1946194 0.84 10/20
SCHEMBL1946349 SCHEMBL1946349 0.83 10/20
SCHEMBL1945902 SCHEMBL1945902 0.82 10/20
SCHEMBL1947342 SCHEMBL1947342 0.82 10/20
SCHEMBL1944620 SCHEMBL1944620 0.80 10/20

Clinical trials — most relevant to KCNA1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease PHASE4NOT_YET_RECRUITING
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery PHASE4RECRUITING
Mutation-specific Therapy for the Long QT Syndrome PHASE2COMPLETED
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients PHASE2COMPLETED
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy PHASE1/PHASE2RECRUITING
Sandostatine® LP and Hyperinsulinism PHASE2COMPLETED
4-Aminopyridine in Episodic Ataxia Type 2 PHASE2WITHDRAWN
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK PHASE1COMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients. nanUNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism nanCOMPLETED
Characteristics of Episodic Ataxia Syndrome nanCOMPLETED
Qatar Cardiovascular Biorepository of AF Patients nanUNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy nanUNKNOWN
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
Gene Study for Infantile Onset Diabetes nanUNKNOWN
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia nanUNKNOWN
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. nanUNKNOWN
The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats nanCOMPLETED
The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats nanCOMPLETED
A Natural History Study of Participants With Potassium Sodium-Activated Channel Subfamily T Member 1 (KCNT1)-Related Epilepsy nanCOMPLETED
Characteristics of Andersen-Tawil Syndrome nanCOMPLETED
Interaction of Potassium and Genetic Risk Variants on Diabetes Risk nanCOMPLETED
Targeting Potassium Channels to Reprogram Glioblastoma Microenvironment: in Vitro and in Vivo Studies nanUNKNOWN
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA) nanUNKNOWN
Comparison Between Epinephrine and Exercise Test in QT Long Syndrome Patients nanUNKNOWN
The Use of Antiarrhythmic Drugs in Pediatrics nanUNKNOWN
Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome nanRECRUITING
Identify the Genes Polymorphisms Related to Non-familial Bradyarrhythmia nanUNKNOWN
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a KCNA1 binder may also engage these)

ProteinNameSimilarity
KCNA2 Potassium voltage-gated channel subfamily A member 2 1.000 landscape →
P22739 1.000 P22739 →
P16388 1.000 P16388 →
Q28293 1.000 Q28293 →
P63142 1.000 P63142 →
P63141 1.000 P63141 →
P10499 1.000 P10499 →
Q9I830 1.000 Q9I830 →
B2RQA1 1.000 B2RQA1 →
Q16322 1.000 Q16322 →
Q09081 1.000 Q09081 →
Q9I829 1.000 Q9I829 →
Q7T199 1.000 Q7T199 →
P16390 1.000 P16390 →
Q9ULS6 0.998 Q9ULS6 →
Q8I4B0 0.998 Q8I4B0 →
G5EFC3 0.997 G5EFC3 →
P15384 0.997 P15384 →
Q9H3M0 0.996 Q9H3M0 →
Q9TT17 0.995 Q9TT17 →
KCNA3 Potassium voltage-gated channel subfamily A member 3 0.995 landscape →
P25122 0.993 P25122 →
Q8BQZ8 0.993 Q8BQZ8 →
Q9XXD1 0.993 Q9XXD1 →
P15385 0.992 P15385 →
Q61423 0.992 Q61423 →
O88759 0.992 O88759 →
KCNA6 Potassium voltage-gated channel subfamily A member 6 0.992 landscape →
P17659 0.991 P17659 →
Q9BQ31 0.991 Q9BQ31 →